Quantcast

Latest Cisplatin Stories

2014-08-05 23:00:31

LifeScienceIndustryResearch.com adds latest Report on “Global and Chinese Cisplatin (CAS 15663-27-1) Industry, 2009-2019 Market Research Report” to its store. Inquire before buying at http://www.lifescienceindustryresearch.com/inquire-before-buying?rname=15033. Dallas, TX (PRWEB) August 06, 2014 Delivery of the Report will take 2-3 working days once order is placed. Global and Chinese Cisplatin (CAS 15663-27-1) Industry, 2009-2019 Market Research Report is a professional and in-depth...

2014-06-18 08:29:42

EAST SETAUKET, N.Y., June 18, 2014 /PRNewswire/ -- The journal Molecular Cancer Therapeutics has published an article on Lixte's lead compound LB-100 entitled "Inhibition of protein phosphatase 2A enhances cytotoxicity and accessibility of chemotherapeutic drugs to hepatocellular carcinomas." The article details a study showing that LB-100 increases the efficacy of two widely used anti-cancer drugs against liver cancers in model systems. Performed at the Zhejiang University School of...

2014-06-17 04:21:42

Proof-of-Concept Trial Targets DNA Repair in Bile Duct Cancers SAN DIEGO and NEW TAIPEI CITY, Taiwan, June 17, 2014 /PRNewswire-iReach/ -- Senhwa Biosciences, Inc. announced today that the Company has initiated a randomized Phase 1b/2 Trial of CX-4945 in combination with gemcitabine and cisplatin for the frontline treatment of patients with bile duct cancers (cholangiocarcinoma). This Proof-of-Concept trial will study the use of CX-4945, a small molecule CK2 inhibitor, to suppress...

2014-05-14 16:28:57

-- Difficult-to-treat squamous NSCLC patients saw clinical benefit with necitumumab plus chemotherapy regimen -- INDIANAPOLIS, May 14, 2014 /PRNewswire/ -- Lung cancer patients with metastatic squamous cell carcinoma have seen few treatment advancements over the last two decades, leaving these patients with a poor prognosis. This is in contrast to the progress seen in nonsquamous non-small cell lung cancer (NSCLC).[1] Results from the largest ever Phase III trial in first-line...

2014-04-29 16:31:09

Polaris Group Scientific Colleagues from Several University Cancer Centers Present Data at 2014 AACR Meeting in San Diego, CA SAN DIEGO, April 29, 2014 /PRNewswire/ -- Polaris Group collaborating scientists from numerous institutions reported results from preclinical studies at the 2014 annual American Association for Cancer Research (AACR) meeting, which showed that certain non-small cell lung cancers (NSCLC), malignant pleural mesothelioma (MPM) and melanomas are more likely to...

2014-04-25 12:26:33

DUBLIN, Apr. 25, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/dj4r99/global_testicular) has announced the addition of the "Global Testicular Cancer Drugs Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 The current trend witnessed by the Global Testicular Cancer Drugs market is combination therapy being used for treating testicular cancer. Several oncologists believe that chemotherapy drugs are most...

2014-04-10 23:24:17

Mexican researchers say an alternative to the standard mesothelioma chemotherapy regimen can not only improve survival and quality of life, but can also save money. Raleigh, NC (PRWEB) April 10, 2014 Scientists in the Thoracic Oncology Unit at Mexico’s National Cancer Institute say continuous infusions of low-dose Gemzar (gemcitabine) with cisplatin appear to be a safe and effective alternative to standard mesothelioma chemotherapy. Click here to read about the new study on the...

2014-04-07 12:33:26

New data demonstrates VAL-083 is superior to standard platinum-based chemotherapy in an established in vivo model of non-small cell lung cancer (NSCLC) VANCOUVER, British Columbia, MENLO PARK, Calif. and SAN DIEGO, April 7, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the presentation of new data in a poster entitled, "In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer." DelMar's data was presented on Sunday, April 6, 2014...

2014-04-04 12:18:55

Researchers from the University of Pittsburgh Cancer Institute (UPCI), a partner with UPMC CancerCenter, have found that an agent that inhibits mitochondrial division can overcome tumor cell resistance to a commonly used cancer drug, and that the combination of the two induces rapid and synergistic cell death. Separately, neither had an effect. These findings will be presented Monday at the annual meeting of the American Association for Cancer Research Annual Meeting 2014. "In our earlier...

2014-03-24 23:24:12

Japanese researchers say the drug Alimta (pemetrexed) in combination with cisplatin should remain the top first-line treatment for malignant pleural mesothelioma. Raleigh, NC (PRWEB) March 24, 2014 Japanese researchers say the drug Alimta (pemetrexed) in combination with cisplatin should remain the top first-line treatment for malignant pleural mesothelioma. Their findings have just been posted by Surviving Mesothelioma at...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related